UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2022 » Volume 30, issue 4 (113) » CLINICAL PROTOCOL FOR TERTIARY (HIGHLY SPECIALIZED) MEDICAL CARE FOR PATIENTS WITH SCHIZOPHRENIA, SCHIZOTYPAL AND DELUSIONAL DISORDERS IN ADULTHOOD

CLINICAL PROTOCOL FOR TERTIARY (HIGHLY SPECIALIZED) MEDICAL CARE FOR PATIENTS WITH SCHIZOPHRENIA, SCHIZOTYPAL AND DELUSIONAL DISORDERS IN ADULTHOOD

Type of Article

  • Scientific Article

In the Section

  • CLINICAL PROTOCOLS
Index UDK:

Pages

  • 77-88

Year / Issue

Download PDF

References

  1. Державний формуляр лікарських засобів. Випуск одинадцятий. Затверджено Міністерством охорони здоров’я України (наказ МОЗ України від 18.04.2019 № 892). Київ, 2019. 1185 с.
  2. Марута Н. О., Білоус В. С. Продромальний період психозу: клініко-психопатологічні та патопсихологічні закономірності формування, критерії діагностики і принципи профілактики // Вісник наукових досліджень. 2017. № 4. С. 81—85. URL: http://nbuv.gov.ua/UJRN/vndt_2017_4_20.
  3. Марута Н. А. Стратегия смены антипсихотического препарата: проблемы и решения // Психиатрия, психотерапия и клиническая психология. 2017. Т. 8, № 1. С. 112—123. URL: https://rucont.ru/efd/582383.
  4. Advancing paternal age and the risk of schizophrenia / Malaspina D., Harlap S., Fennig S. [et al.] // Arch. Gen. Psychiatry. 2001. 58. 361—367. DOI: https://doi.org/10.1001/archpsyc.58.4.361.
  5. Aleman A., Kahn R. S., Selten J. P. Sex differences in the risk of schizophrenia: evidence from meta-analysis // Archives of general psychiatry. 2003; 60(6): 565—571. DOI: https://doi.org/10.1001/archpsyc.60.6.565.
  6. Antipsychotic drug effects on brain morphology in first episode psychosis / Lieberman J. A., Tollefson G. D., Charles C. [et al.]; HGDH Study Group // Arch. Gen. Psychiatry. 2005. 62. 361—370. DOI: https://doi.org/10.1001/archpsyc.62.4.361.
  7. Association of Antipsychotic Polypharmacy vs Monotherapy with Psychiatric Rehospitalization Among Adults with Schizophrenia / Tiihonen  , Taipale  H., Mehtälä  J. [et al.] // JAMA Psychiatry. 2019 May 1; 76 (5): 499—507. PMID: 30785608.
  8. Brain volume changes in the first year of  illness and 5-year outcome of schizophrenia / Cahn W., van Haren N. E., Hulshoff Pol H. E. [et al.]  // Br.  Psychiatry. 2006 Oct. 189. 381—2. DOI: https://doi.org/10.1192/bjp.bp.105.015701.
  9. British National Formulary. National Institute for Health and Care Excellence. 2019. URL: https://bnf.nice.org.uk/.
  10. Brown S., Kim M., Mitchell C. & Inskip H. Twenty-five year mortality of a community cohort with schizophrenia // Br J Psychiatry. 2010; 196: 116—21. DOI: https://doi.org/10.1192/bjp. bp.109.067512.
  11. Casey D. E., Zorn S. H. The Pharmacology of Weight Gain with Antipsychotics // J. Clin. Psych. 2001. 62 (suppl. 7). P. 4—10. PMID: 11346195.
  12. Compounded brain volume deficits in schizophrenia-alcoholism comorbidity / Mathalon D. H., Pfefferbaum A., Lim K. O. [et al.] // Arch. Gen. Psychiatry. 2003 Mar. 60(3). 245—52. DOI: https://doi.org/10.1001/archpsyc.60.3.245.
  13. Do psychiatric registries include all persons with schizophrenia in the general population? A population-based longitudinal study / M. Weiser, N. Werbeloff, B. P. Dohrenwend [et al.] // Schizophrenia research. 2012. Vol. 135 (1—3): 187—191. URL: https://doi.org/10.1016/j.schres.2011.12.023.
  14. Effectiveness of antipsychotics drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial / Kahn R. S., Fleischhacker W. W., Boter H. [et al.]; EUFEST study group // Lancet. 2008. Vol. 371, No. 9618. P. 1085— 1097. DOI: https://doi.org/10.1016/S0140-6736(08)60486-9.
  15. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring / Brown A. S., Hooton J., Schaefer C. A. [et al.] // Am. J. Psychiatry. 2004 May. 161 (5). 889—95. DOI: https://doi.org/10.1176/appi.ajp.161.5.889.
  16. Elevated prenatal homocysteine levels as a risk factor for schizophrenia / Brown A. S., Bottiglieri T., Schaefer C. A. [et al.] // Arch. Gen. Psychiatry. 2007 Jan. 64 (1). 31—9. DOI: https://doi.org/10.1001/archpsyc.64.1.31.
  17. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs / Bai O., Chlan-Fourney J., Bowen R. [et al.] // J. Neurosci. Res. 2003 Jan. 1; 71(1). 127—31. DOI: https://doi.org/10.1002/jnr.10440.
  18. Fusar-Poli P., McGorry P.D., Kane J.M. Improving outcomes of first-episode psychosis: an overview // World Psychiatry. 2017. 16 (3): 251—65. DOI: https://doi.org/10.1002/wps.20446.
  19. Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia / Roffman J.L., Brohawn D. G., Nitenson A. Z. [et al.] // Schizophrenia Bulletin. March 2013. Vol. 39, Issue 2. P. 330—338. DOI: https://doi.org/10.1093/schbul/sbr150.
  20. Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016 / F. J. Charlson, A. J. Ferrari, D. F. Santomauro [et al.] // Schizophrenia Bulletin. 2018. Vol. 44, Issue 6. P. 1195—1203. DOI: https://doi.org/10.1093/schbul/sby058.
  21. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017 / GBD 2017 Disease and Injury Incidence and Prevalence Collaborators // The Lancet. Global Health Metrics. 2018. Vol. 392, Issue 10159. P. 1789—1858. DOI: https://doi.org/10.1016/S0140-6736(18)32279-7.
  22. Goff D. C., Coyle J. T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia // Am. J. Psychiatry. 2001 Sep. 158 (9). 1367—77. DOI: https://doi.org/10.1176/appi.ajp.158.9.1367.
  23. Goff D. C., Heckers S., Freudenreich O. Schizophrenia // Medical Clinics of North America. 2001. Vol. 85, Issue 3. P. 663— 89. DOI: https://doi.org/10.1016/S0025-7125(05)70335-7.
  24. Guidelines for the Pharmacotherapy of Schizophrenia in Adults / G. Remington, D. Addington, W. Honer [et al.]; LRCP&SI, FRCP // The Canadian Journal of Psychiatry. 2017 Sep; 62(9): 604—616. DOI: https://doi.org/10.1177/0706743717720448.
  25. Harrison P. J., Weinberger D. R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence // Molec. Psychiatry. 2005. 10. 40—68. DOI: https://doi.org/10.1038/sj.mp.4001558.
  26. Laursen T. M., Nordentoft M., Mortensen P. Excess early mortality in schizophrenia // Annual Review of Clinical Psychology. 2014; 10, 425—438. DOI: https://doi.org/10.1146/annurevclinpsy-032813-153657.
  27. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance / Kuipers E., Yesufu-Udechuku A. (reviewer), Taylor C. (editor), Kendall T. (consultant psychiatrist) // BMJ. 2014; 348: g1173. URI: https://www.bmj.com/content/348/bmj.g1173.
  28. McGrath J. J. Myths and plain truths about schizophrenia epidemiology — the NAPE lecture 2004 // Acta Psychiatr Scand. 2005; 111(1): 4—11. DOI: https://doi.org/10.1111/j.1600-0447.2004.00467.x.
  29. Negative symptoms of schizophrenia: new developments and unanswered research questions / [S. Galderisi, A. Mucci, R. W. Buchanan, C. Arango] // The Lancet Psychiatry. 2018; 5 (8): 664—677. DOI: https://doi.org/10.1016/S2215-0366(18)30050-6.
  30. Owen M. J., Williams N. M., O’Donovan M. C. The molecular genetics of schizophrenia: new findings promise new insights // Molec. Psychiatry. 2004. 9. 14—27. DOI: https://doi.org/10.1038/sj.mp.4001444.
  31. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected firstdegree relatives / S. Galderisi, A. Rossi, P. Rocca [et al.]; Italian Network for Research on Psychoses // Schizophr Res. 2016; 175 (1—3): 154—160. DOI: https://doi.org/10.1016/j.schres.2016.04.043.
  32. Pharmacological Treatment of Schizophrenia and Related Psychoses (including First Episode Psychosis) : Prescribing Guideline (PG10), NHS, 2019. URL: https://www.dpt.nhs.uk/download/vGeUDUfP7j.
  33. Pillai A., Terry A. V. Jr, Mahadik S. P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus // Schizophr. Res. 2006 Feb. 15; 82(1). 95—106. DOI: https://doi.org/10.1016/j.schres.2005.11.021.
  34. Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins / E. F. Torrey, E. H. Taylor, H. S. Bracha [et al.] // Schizophr. Bull. 1994. 20(3). 423—32. DOI: https://doi.org/10.1093/schbul/20.3.423.
  35. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. NICE, 2014. URL: https://www.nice.org.uk/guidance/cg178.
  36. Royal College of Psychiatrists; Report of the National Audit of Schizophrenia (NAS) 2012. London : Healthcare Quality Improvement Partnership, 2012. Publication number : CCQI138.
  37. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middleincome countries / Lora A., Kohn R., Levav I. [et al.] // Bulletin World Health Organization. 2012. 90(1): 47—54, 54A-54B. DOI: https://doi.org/10.2471/BLT.11.089284.
  38. The American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. Third Edition. 2021. DOI: https://doi.org/10.1176/appi.books.9780890424841.
  39. The association between premorbid cognitive ability and social functioning and suicide among young men: A historical-prospective cohort study / M. Weiser, D. Fenchel, N. Werbeloff [et al.] // European Neuropsychopharmacology. 2017; 27 (1): 1—7. DOI: https://doi.org/10.1016/j.euroneuro.2016.11.015.
  40. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches / Lieberman J. A., Perkins D., Belger A. [et al.] // Biol. Psychiatry. 2001 Dec. 1; 50(11). 884—97. DOI: https://doi.org/10.1016/s0006-3223(01)01303-8.
  41. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years differences in network structure between recovered and non-recovered patients / S. Galderisi, P. Rucci, A. Mucci [et al.] // World Psychiatry. 2020; 19 (1): 81—91. DOI: https://doi.org/10.1002/wps.20700.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»